EUVIMEDEUVIMED entdecken
Editorial

How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability

M Raheel Khan iD, Patrick M Forde iD

Journal of Clinical Oncology · 20.04.2026 · 44 (12) · 1065-1067

DOI: 10.1200/jco-25-03105 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2026. Verfasst von M Raheel Khan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Trinity St James's Cancer Institute, Trinity College, Dublin, Ireland. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Trinity St James's Cancer Institute, Trinity College, Dublin, Ireland.

ORCID-Profile: M Raheel Khan, Patrick M Forde

Zitieren

APA

Khan, M. R., & Forde, P. M. (2026). How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability. Journal of Clinical Oncology, 44(12), 1065-1067. https://doi.org/10.1200/jco-25-03105

Vancouver

Khan MR, Forde PM. How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability. Journal of Clinical Oncology. 2026;44(12):1065-1067. doi:10.1200/jco-25-03105

BibTeX
@article{Khan2026,
  author = {Khan, M Raheel and Forde, Patrick M},
  title = {How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {12},
  pages = {1065--1067},
  doi = {10.1200/jco-25-03105}
}
Kostenlos starten →